Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2020

View Archived Issues

Faulty exon splicing is cause of rare subtype of Parkinson's disease, pointing to new drug targets

Positive preclinical data for novel COVID-19 vaccine, ACvac1

Key initial results reported from phase I study of CPI-006 for patients with COVID-19

FDA clears IND for phase I study of APR-003

Room for improvement in T-cell repertoire profiling

Results from phase II CENTAUR study of sodium phenylbutyrate/taurursodiol in ALS

Voronoi patents new RET inhibitors

Galapagos discloses PASK inhibitors

Aerie Pharmaceuticals presents new Rho and JAK inhibitors

Discovery of novel orally active and selective PI3Kalpha inhibitor

Constellation Pharmaceuticals discovers new CBP and KAT3B inhibitors

New phase II trial examines suprachoroidal administration of AU-011 in primary choroidal melanoma

Proof-of-concept study of ziritaxestat in diffuse cutaneous systemic sclerosis meets endpoint

New antibacterials presented by Viridias

Topadur begins phase I study of TOP-N53 for wound healing

QBW-251: a CFTR potentiator in phase II for the treatment of COPD

Phase III trial of Fasenra in nasal polyposis meets coprimary endpoints

Bicycle opens phase I/II study of BT-8009 in advanced solid tumors

FCN-437c enters phase II trial in China for advanced breast cancer

Pentamidine targets S100B to improve experimental multiple sclerosis

SanBio reports new phase IIb analyses for SB-623 in chronic motor deficit from ischemic stroke

Gemini begins phase IIa study of GEM-103 for dry AMD

Novartis describes discovery and clinical results with ERK1/2 inhibitor LTT-462

Sutro reports updated phase I data on STRO-002 in advanced ovarian cancer

KITE study of Beovu in DME meets primary and key secondary endpoints

Dimerix reports phase II data on DMX-200 in diabetic kidney disease

Enanta begins phase I study of EDP-297 for NASH

FDA approves Trelegy Ellipta for asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...